BioPharmX Presents BPX-01 Topical Minocycline Gel Acne Data at SDEF's 17th Annual Las Vegas Dermatology Seminar
MENLO PARK, Calif., Nov. 10, 2016 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, will present results from two clinical studies comparing oral and topical minocycline during a poster presentation at the Skin Disease Education Foundation's 17th Annual Las Vegas Dermatology Seminar today through Saturday.
Presentation Details:
Title: "BPX-01 Minocycline 1% topical Gel for the Treatment of Acne Vulgaris"
Author: AnnaMarie Daniels
Location: The Cosmopolitan Las Vegas, 4th Floor, Belmont 4-8 Ballroom
Dates: November 10-12, 2016
The poster will show that daily application of BPX-01 one percent topical minocycline gel for four weeks was well tolerated and resulted in a statistically significant reduction in P. acnes bacteria in the per protocol population with no detectable minocycline in the plasma. Prior observations indicate that BPX-01 was effectively delivered into the pilosebaceous units, which was confirmed clinically by a reduction in P. acnes counts without evidence of systemic exposure. Conversely, our second study indicated that daily administration of oral minocycline for the same period of time resulted in high circulating levels of minocycline. These two studies suggest that BPX-01 topical minocycline may have a favorable pharmacokinetic advantage over oral minocycline for the treatment of acne vulgaris. A confirmatory phase 2b clinical study to support this observation is in progress.
